Mepolizumab for eosinophilic chronic obstructive pulmonary disease

New England Journal of Medicine

Volumn 377, Issue 17, 2017, Pages 1613-1629

  Pavord, I D ^a   Chanez, P ^c   Criner, G J ^d   Kerstjens, H A M ^e   Korn, S ^f   Lugogo, N ^g   Martinot, J B ⁱ   Sagara, H ^j   Albers, F C ^h   Bradford, E S ^h   Harris, S S ^h   Mayer, B ^b   Rubin, D B ^h   Yancey, S W ^h   Sciurba, F C ^k  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c AIX MARSEILLE UNIVERSITY   (France)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^j SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; INTERLEUKIN 5; MEPOLIZUMAB; MONOCLONAL ANTIBODY; PLACEBO; BIOLOGICAL MARKER;

ADVERSE DRUG REACTION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; ADULT; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; EOSINOPHIL; IMMUNOLOGY; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; MIDDLE AGED; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85032506448     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1708208     Document Type: Article

References (31)

1. GOLD 2017: global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease, 2017 (http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/).
2. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5.
3. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-700.
4. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
5. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42.
6. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014;44:789-91.
7. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55.
8. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017;389:1919-29.
9. Mullerova H, Maskell J, Meeraus WH, Galkin D, Albers FC, Gait C. Characterization of COPD patients treated with inhaled triple therapy containing inhaled corticosteroids [ICS], long-acting beta2-agonists [LABA], and long-acting muscarinic antagonists [LAMA] in the UK. Am J Respir Crit Care Med 2017;195:A4986. abstract.
10. Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108:250-7.
11. Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol 2016;16:186-200.
12. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
13. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
14. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5:390-400.
15. Yancey S, Albers F, Gunsoy N, Harris S, Keene ON. Effect of mepolizumab on exacerbations in asthma patients with features common in COPD. Am J Respir Crit Care Med 2017;195:A4683. abstract.
16. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
17. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19:398-404.
18. Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. Chest 2007;132:456-63.
19. Jones PW, Forde Y. St George’s Respiratory Questionnaire for COPD Patients (SGRQ-C): manual. London: University of London, 2012 (http://www.healthstatus.sgul.ac.uk/SGRQ_download/sgrq-c-manual-april-2012.pdf).
20. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54.
21. Jones PW, Shahrour N, Nejjari C, et al. Psychometric evaluation of the COPD Assessment Test: data from the BREATHE study in the Middle East and North Africa region. Respir Med 2012;106:Suppl 2:S86-S99.
22. Keene ON, Roger JH, Hartley BF, Kenward MG. Missing data sensitivity analysis for recurrent event data using controlled imputation. Pharm Stat 2014;13: 258-64.
23. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016;4:549-56.
24. Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014;2:891-901.
25. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 2016;4: 731-41.
26. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13.
27. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192: 523-5.
28. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 2016;71:118-25.
29. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-23.
30. Calverley PMA, Stockley RA, Seemungal TAR, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139:505-12.
31. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7.